This site is intended for healthcare professionals

Phase III SPI2 trial of MD 1003 fails to meet endpoints in multiple sclerosis.- MedDay Pharma

Read time: 1 mins
Published:11th Mar 2020
Condition: Multiple Sclerosis
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest